Research programme: Tie2 expressing monocytes immuno gene therapies - Genenta Science
Alternative Names: Research programme: TEMs immuno gene therapies - Genenta ScienceLatest Information Update: 23 Jun 2022
At a glance
- Originator Unknown
- Developer Genenta Science; Unknown
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Jun 2022 Genenta Sciences has patent protection for links with SR-Tiget and benefit from exclusive options originated by the preclinical programs conducted in SR-Tiget laboratories and relating to core science (Genenta Sciences website, June 2022)
- 15 Jun 2022 Preclinical trials in Solid tumours in Italy (Parenteral) (Genenta Sciences pipeline, June 2022)